for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

China NT Pharma Group Company Ltd

1011.HK

Latest Trade

0.44HKD

Change

-0.03(-6.38%)

Volume

343,500

Today's Range

0.44

 - 

0.47

52 Week Range

0.44

 - 

1.39

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
0.47
Open
0.46
Volume
343,500
3M AVG Volume
20.57
Today's High
0.47
Today's Low
0.44
52 Week High
1.39
52 Week Low
0.44
Shares Out (MIL)
1,904.64
Market Cap (MIL)
838.04
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

China NT Pharma Group To Buy 40% Stake In Hong Kong WD Pharmaceutical

China NT Pharma Group Company Expects Profit For Six Months Ending 30 June 2019

China NT Pharma To Place Convertible Bonds In Principal Amount Of Up To HK$192.8 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About China NT Pharma Group Company Ltd

CHINA NT PHARMA GROUP COMPANY LIMITED is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company mainly conducts its businesses through two segments. The Proprietary Product Production and Sales segment is engaged in the production and sales of NT branded products and generic drugs through its subsidiaries. The Miacalcic segment is engaged in the sales and marketing of miacalcic injectable and nasal spray branded products for treatment of bone pain caused by osteolysis and lower bone mass, as well as sub-licensing of intellectual property rights and distribution rights.

Industry

Biotechnology & Drugs

Contact Info

5F

Chenghui Mansion, No.45 Nanchang Road

+852.null.28081606

http://www.ntpharma.com

Executive Leadership

Tit Ng

Executive Chairman of the Board, Chief Executive Officer

Fei Wang

Chief Financial Officer, Executive Director

Baoming Ge

General Manager of Corporate Development and Product Research and Development Centre

Yu Chin

Executive Director

Weizhong Wu

Executive Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
1.70
Price To Book (MRQ)
1.06
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
139.50
LT Debt To Equity (MRQ)
7.59
Return on Investment (TTM)
-58.65
Return on Equity (TTM)
-27.56

Latest News

Latest News

BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo

* PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO®

BRIEF-China NT Pharma Group Co Appoints Wang Fei As CFO

* APPOINTS WANG FEI AS CFO Source text for Eikon: Further company coverage:

BRIEF-China Nt Pharma Group Co ‍Fy Net Profit Attributable RMB 165.2 Mln VS RMB 116.2 Mln​

* FY NET PROFIT ATTRIBUTABLE RMB165.2 MILLION VERSUS RMB116.2 MILLION

BRIEF-China Nt Pharma Group Co Says Co To Cease Libod Sales & Promotion From Dec. 31, 2017

* ENTERS DEAL TO TERMINATE SALES & PROMOTION DEAL, CO TO CEASE LIBOD SALES & PROMOTION FROM DEC. 31, 2017 Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-China NT Pharma Group Co says HY profit attributable to equity shareholders up 61.1 pct

* HY profit attributable to equity shareholders of company increased by 61.1% from RMB50.1 million to RMB80.7 million

BRIEF-China NT Pharma expects increase in net profit for six months ended 30 June 2017

* Group expects to record an increase in net profit by about 50 percent for six months ended 30 June 2017

BRIEF-China NT Pharma enters deal to issue 325 mln shares at HK$1.83 per share

* Co agreed to issue aggregate of 325 million convertible preference shares at a price of HK$1.83 per convertible preference shares Source text (http://bit.ly/2pRmc0t) Further company coverage:

BRIEF-China Nt Pharma obtains certification from China Food and Drug Administration

* Jiangsu NT Biopharma successfully obtained new good manufacturing practices certification from China Food and Drug Administration

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up